We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
View All

Blog - Pharmaceuticals, Medicinal Chemical And Botanical Products

Novo Nordisk Stock Surges as New Weight Loss Drug Shows Promise
Novo Nordisk Stock Surges as New Weight Loss Drug Shows Promise
Jan 24, 2025
Eye 231

Novo Nordisk's stock rises as new weight loss drug, amycretin, shows up to 22% weight loss in trials, boosting investor confidence.
Moderna's Norovirus Vaccine Trial Advances Amid Surge in U.S. Cases
Moderna's Norovirus Vaccine Trial Advances Amid Surge in U.S. Cases
Jan 23, 2025
Eye 263

Explore Moderna's ongoing phase three norovirus vaccine trial targeting urgent prevention needs amid rising outbreaks in the U.S.
Mitsubishi Chooses Bain Capital for Major Pharma Deal
Mitsubishi Chooses Bain Capital for Major Pharma Deal
Jan 20, 2025
Eye 287

Mitsubishi Chemical selects Bain Capital for Tanabe Mitsubishi Pharma acquisition in a deal surpassing $3.2 billion, aiming to streamline operations.
Moderna Secures an Additional $590 Million for Influenza Vaccine Development
Moderna Secures an Additional $590 Million for Influenza Vaccine Development
Jan 18, 2025
Eye 230

Moderna has secured $590 million to enhance pandemic influenza vaccine development, focusing on mRNA technology and expanding human trials.
Medicare to Negotiate Prices of Weight Loss Drugs like Ozempic and Wegovy
Medicare to Negotiate Prices of Weight Loss Drugs like Ozempic and Wegovy
Jan 17, 2025
Eye 105

Discover how Medicare's new price negotiations for popular weight loss drugs like Ozempic and Wegovy aim to reduce costs and impact global pharmaceutical trade.
Bristol Myers Squibb's Cobenfy Revolutionizing Alzheimer's Treatment
Bristol Myers Squibb's Cobenfy Revolutionizing Alzheimer's Treatment
Jan 15, 2025
Eye 155

Bristol Myers Squibb introduces Cobenfy, a landmark drug aimed at treating Alzheimer's-related psychosis and agitation, potentially transforming patient care and economic prospects.
Biogen's Growth Strategy Focuses on New Launches Over Acquisitions
Biogen's Growth Strategy Focuses on New Launches Over Acquisitions
Jan 15, 2025
Eye 219

Biogen aims for revenue growth through new product launches by 2028, emphasizing Alzheimer's research over acquisitions, as shared by CEO Chris Viehbacher at the JP Morgan Healthcare Conference.
Reckitt Benckiser to Boost US Manufacturing Amid Trade Policy Changes
Reckitt Benckiser to Boost US Manufacturing Amid Trade Policy Changes
Jan 15, 2025
Eye 181

Reckitt Benckiser is investing $200 million to boost US manufacturing, creating 300 jobs and reducing import dependency amid potential Trump administration tariffs.
Eli Lilly Revises Sales Expectations for Key Drugs
Eli Lilly Revises Sales Expectations for Key Drugs
Jan 14, 2025
Eye 103

Eli Lilly revises sales forecasts for Zepbound and Mounjaro, citing slower growth. Future revenue predictions remain optimistic.
Johnson & Johnson Expands Neurological Disorder Portfolio with Intra-Cellular Acquisition
Johnson & Johnson Expands Neurological Disorder Portfolio with Intra-Cellular Acquisition
Jan 14, 2025
Eye 209

Johnson & Johnson enhances its neurological disorder treatment portfolio by acquiring Intra-Cellular Therapies for $14.6 billion, positioning it for future growth and competition with biosimilars.
Pfizer Intensifies Efforts in Obesity Drug Development
Pfizer Intensifies Efforts in Obesity Drug Development
Jan 13, 2025
Eye 110

Pfizer is accelerating the development of an experimental obesity drug, a strategic move that aligns with rising global demand for innovative chronic health treatments.
Eli Lilly Anticipates Approval for Innovative Weight Loss Pill
Eli Lilly Anticipates Approval for Innovative Weight Loss Pill
Jan 13, 2025
Eye 132

Eli Lilly is gearing up for approval of its new weight loss pill, orforglipron, projected for early 2024, offering a promising alternative to injectable options in the expanding weight loss market.
Show more